Allen Buxton
About
Allen Buxton is a scholar working on Pulmonary and Respiratory Medicine, Neurology and Pathology and Forensic Medicine.
According to data from OpenAlex, Allen Buxton has authored 49 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 16 papers in Neurology and 15 papers in Pathology and Forensic Medicine. Recurrent topics in Allen Buxton's work include Lymphoma Diagnosis and Treatment (15 papers), Neuroblastoma Research and Treatments (14 papers) and Sarcoma Diagnosis and Treatment (11 papers). Allen Buxton is often cited by papers focused on Lymphoma Diagnosis and Treatment (15 papers), Neuroblastoma Research and Treatments (14 papers) and Sarcoma Diagnosis and Treatment (11 papers). Allen Buxton collaborates with scholars based in United States, Canada and Switzerland. Allen Buxton's co-authors include C. Patrick Reynolds, John M. Maris, Katherine K. Matthay, Susan L. Cohn, Wendy B. London, Robert C. Seeger, Alice L. Yu, Stephan A. Grupp, Susan G. Kreissman and Judith G. Villablanca and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Allen Buxton
47 papers receiving 3.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Allen Buxton United States | 21 | 1.8k | 1.0k | 977 | 685 | 528 | 49 | 3.1k | ||
| Nick Bown United Kingdom | 30 | 1.3k 0.7× | 1.3k 1.2× | 663 0.7× | 409 0.6× | 593 1.1× | 74 | 3.1k | ||
| Howard M. Katzenstein United States | 36 | 1.4k 0.8× | 1.2k 1.2× | 978 1.0× | 194 0.3× | 707 1.3× | 111 | 3.5k | ||
| Chiaki Nakaseko Japan | 31 | 625 0.3× | 776 0.8× | 675 0.7× | 765 1.1× | 122 0.2× | 166 | 3.5k | ||
| M. Fevzi Özkaynak United States | 19 | 1.4k 0.8× | 854 0.8× | 783 0.8× | 236 0.3× | 432 0.8× | 66 | 2.4k | ||
| Isabelle Aerts France | 28 | 564 0.3× | 839 0.8× | 761 0.8× | 695 1.0× | 306 0.6× | 125 | 2.6k | ||
| Daobin Zhou China | 28 | 890 0.5× | 633 0.6× | 1.0k 1.0× | 762 1.1× | 96 0.2× | 312 | 3.4k | ||
| Arlene Naranjo United States | 33 | 2.5k 1.4× | 1.6k 1.5× | 741 0.8× | 321 0.5× | 1.1k 2.0× | 110 | 3.4k | ||
| Sophie Camilleri‐Broët France | 28 | 599 0.3× | 611 0.6× | 944 1.0× | 497 0.7× | 343 0.6× | 82 | 2.5k | ||
| Thorsten Simon Germany | 34 | 4.3k 2.4× | 2.1k 2.0× | 921 0.9× | 714 1.0× | 1.8k 3.4× | 111 | 5.2k | ||
| Edwin C. Douglass United States | 31 | 608 0.3× | 1.5k 1.4× | 826 0.8× | 371 0.5× | 368 0.7× | 70 | 3.3k |
Countries citing papers authored by Allen Buxton
Since
Specialization
Citations
This map shows the geographic impact of Allen Buxton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allen Buxton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allen Buxton more than expected).
Fields of papers citing papers by Allen Buxton
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Allen Buxton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allen Buxton. The network helps show where Allen Buxton may publish in the future.
Co-authorship network of co-authors of Allen Buxton
This figure shows the co-authorship network connecting the top 25 collaborators of Allen Buxton. A scholar is included among the top collaborators of Allen Buxton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allen Buxton. Allen Buxton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Indelicato, Daniel J., Safia K. Ahmed, Mark Krailo, et al.. (2025). Preoperative Radiotherapy in Patients With Localized Ewing Sarcoma Enrolled on AEWS1031: A Report From the Children's Oncology Group. Pediatric Blood & Cancer. 72(8). e31820–e31820.
2.
Buxton, Allen, et al.. (2025). Dose-Dependent PFESA-BP2 Exposure Increases Risk of Liver Toxicity and Hepatocellular Carcinoma. SHILAP Revista de lepidopterología. 47(2). 98–98.
3.
Shulman, David S., Kelly Klega, Allen Buxton, et al.. (2024). Association of elevated ctDNA burden following one cycle of chemotherapy with inferior outcomes for patients with metastatic Ewing sarcoma: A report from the Children’s Oncology Group (COG).. Journal of Clinical Oncology. 42(16_suppl). 10018–10018.
4.
Cash, Thomas F., Mark Krailo, Allen Buxton, et al.. (2023). Long-Term Outcomes in Patients With Localized Ewing Sarcoma Treated With Interval-Compressed Chemotherapy on Children's Oncology Group Study AEWS0031. Journal of Clinical Oncology. 41(30). 4724–4728.
5.
Ahmed, Safia K., Odion Binitie, Mark Krailo, et al.. (2023). Evaluation of local control strategies on patterns of treatment failure in patients with localized ewing sarcoma treated on AEWS1031: A report from the children’s oncology group.. Journal of Clinical Oncology. 41(16_suppl). 11529–11529.
6.
Hingorani, Pooja, Mark Krailo, Allen Buxton, et al.. (2022). Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group. European Journal of Cancer. 172. 264–275.
7.
Su, Jack, Lindsay Kilburn, David B. Mansur, et al.. (2021). Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children’s Oncology Group report. Neuro-Oncology. 24(4). 655–664.
8.
Warren, Katherine E., Gilbert Vézina, Allen Buxton, et al.. (2021). EPCT-16. LENALIDOMIDE ACTIVITY IN PILOCYTIC ASTROCYTOMA AND OPTIC PATHWAY GLIOMAS: REPORT ON CHILDREN’S ONCOLOGY GROUP ACNS1022. Neuro-Oncology. 23(Supplement_1). i50–i50.
9.
DuBois, Steven G., Mark Krailo, Allen Buxton, et al.. (2021). Patterns of Translocation Testing in Patients Enrolling in a Cooperative Group Trial for Newly Diagnosed Metastatic Ewing Sarcoma. Archives of Pathology & Laboratory Medicine. 145(12). 1564–1568.
10.
Mascarenhas, Leo, Allen Buxton, Steven G. DuBois, et al.. (2020). Maximum tumor dimension and tumor volume as prognostic factors in patients with newly diagnosed localized Ewing sarcoma (ES)- a report from the Children’s Oncology Group (COG).. Journal of Clinical Oncology. 38(15_suppl). 11529–11529.
11.
Kopp, Lisa M., Suman Malempati, Mark Krailo, et al.. (2019). Phase II trial of the glycoprotein non-metastatic B-targeted antibody–drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group. European Journal of Cancer. 121. 177–183.
12.
Frazer, J. Kimble, Kevin J. Li, Paul J. Galardy, et al.. (2018). Excellent outcomes in children and adolescents with CNS + Burkitt lymphoma or other mature B‐NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB /LMB 96 and COG ANHL 01P1. British Journal of Haematology. 185(2). 374–377.
13.
Jakacki, Regina I., Kenneth J. Cohen, Allen Buxton, et al.. (2016). Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. Neuro-Oncology. 18(10). 1442–1450.
14.
Kreissman, Susan G., Robert C. Seeger, Katherine K. Matthay, et al.. (2013). Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. The Lancet Oncology. 14(10). 999–1008.
15.
Ashley, David M., Thomas E. Merchant, Douglas Strother, et al.. (2012). Induction Chemotherapy and Conformal Radiation Therapy for Very Young Children With Nonmetastatic Medulloblastoma: Children's Oncology Group Study P9934. Journal of Clinical Oncology. 30(26). 3181–3186.
16.
Yu, Alice L., Andrew L. Gilman, M. Fevzi Özkaynak, et al.. (2010). Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma. New England Journal of Medicine. 363(14). 1324–1334.
17.
Castellino, Sharon M., Todd A. Alonzo, Allen Buxton, et al.. (2007). Outcomes in childhood AML in the absence of transplantation in first remission—Children's Cancer Group (CCG) studies 2891 and CCG 213. Pediatric Blood & Cancer. 50(1). 9–16.
18.
Alonzo, Todd A., Robert J. Wells, William G. Woods, et al.. (2005). Postremission therapy for children with acute myeloid leukemia: the children's cancer group experience in the transplant era. Leukemia. 19(6). 965–970.
19.
Alonzo, Todd A., Nathan L. Kobrinsky, Alexander Aledo, et al.. (2002). Impact of Granulocyte Colony-Stimulating Factor Use During Induction for Acute Myelogenous Leukemia in Children: A Report From the Children's Cancer Group. Journal of Pediatric Hematology/Oncology. 24(8). 627–635.
20.
Hobbiss, J, et al.. (1984). A comparison of serum albumin, age and the sheffield prognostic index in the prediction of surgical complications. Clinical Nutrition. 3(4). 227–230.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Nick Bown Breakdown of academic impact, for papers by Howard M. Katzenstein Breakdown of academic impact, for papers by Chiaki Nakaseko Breakdown of academic impact, for papers by M. Fevzi Özkaynak Breakdown of academic impact, for papers by Isabelle Aerts Breakdown of academic impact, for papers by Daobin Zhou Breakdown of academic impact, for papers by Arlene Naranjo Breakdown of academic impact, for papers by Sophie Camilleri‐Broët Breakdown of academic impact, for papers by Thorsten Simon Breakdown of academic impact, for papers by Edwin C. Douglass